

Benjamin Kasenda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7233912/publications.pdf>

Version: 2024-02-01

89
papers

3,190
citations

147801

31
h-index

168389

53
g-index

91
all docs

91
docs citations

91
times ranked

4946
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1045.	7.4	265
2	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	6.4	256
3	First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)â€”a systematic review and individual patient data meta-analysis. <i>Annals of Oncology</i> , 2015, 26, 1305-1313.	1.2	152
4	High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). <i>Leukemia</i> , 2017, 31, 846-852.	7.2	134
5	A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. <i>Journal of Clinical Epidemiology</i> , 2016, 80, 8-15.	5.0	130
6	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e388-e397.	4.6	128
7	Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. <i>Annals of Oncology</i> , 2011, 22, 2080-2085.	1.2	107
8	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 346-354.	5.8	98
9	Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphomaâ€”a long-term follow-up study. <i>Annals of Oncology</i> , 2012, 23, 2670-2675.	1.2	93
10	Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. <i>Haematologica</i> , 2013, 98, 765-770.	3.5	82
11	Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 1-11.	5.0	77
12	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. <i>BMJ</i> , The, 2014, 349, g4539-g4539.	6.0	74
13	High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. <i>Leukemia</i> , 2017, 31, 2623-2629.	7.2	72
14	Web-Based Stress Management for Newly Diagnosed Patients With Cancer (STREAM): A Randomized, Wait-List Controlled Intervention Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 780-788.	1.6	71
15	High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. <i>Bone Marrow Transplantation</i> , 2017, 52, 1113-1119.	2.4	58
16	Meta-analyses: what they can and cannot do. <i>Swiss Medical Weekly</i> , 2012, 142, w13518.	1.6	57
17	Rituximab in primary central nervous system lymphomaâ€”A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	1.7	54
18	Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791.	2.8	53

#	ARTICLE	IF	CITATIONS
19	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). <i>BMC Cancer</i> , 2016, 16, 282.	2.6	53
20	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. <i>JAMA Network Open</i> , 2020, 3, e2024406.	5.9	53
21	The reporting of studies using routinely collected health data was often insufficient. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 104-111.	5.0	51
22	Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade. <i>BioMed Research International</i> , 2017, 2017, 1-5.	1.9	49
23	Stem Cell Migration: A Quintessential Stepping Stone to Successful Therapy. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 89-103.	1.3	47
24	Planning and reporting of quality-of-life outcomes in cancer trials. <i>Annals of Oncology</i> , 2015, 26, 1966-1973.	1.2	47
25	Completion and Publication Rates of Randomized Controlled Trials in Surgery. <i>Annals of Surgery</i> , 2015, 262, 68-73.	4.2	45
26	Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. <i>BMC Cancer</i> , 2014, 14, 728.	2.6	42
27	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system—an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020, 189, 879-887.	2.5	41
28	Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. <i>British Journal of Haematology</i> , 2019, 184, 957-968.	2.5	39
29	¹⁸ F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma. <i>Journal of Nuclear Medicine</i> , 2013, 54, 184-191.	5.0	37
30	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. <i>Cell Reports</i> , 2019, 28, 3367-3380.e8.	6.4	37
31	The role of whole brain radiation in primary CNS lymphoma. <i>Blood</i> , 2016, 128, 32-36.	1.4	35
32	High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. <i>Blood Advances</i> , 2020, 4, 3378-3381.	5.2	34
33	Learning from failure - rationale and design for a study about discontinuation of randomized trials (DISCO study). <i>BMC Medical Research Methodology</i> , 2012, 12, 131.	3.1	33
34	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck—a multicentre, retrospective analysis. <i>Radiation Oncology</i> , 2019, 14, 32.	2.7	30
35	A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3026-3034.	7.0	29
36	Premature Discontinuation of Randomized Trials in Critical and Emergency Care. <i>Critical Care Medicine</i> , 2016, 44, 130-137.	0.9	28

#	ARTICLE	IF	CITATIONS
37	Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study. <i>Journal of Pediatrics</i> , 2017, 184, 209-214.e1.	1.8	23
38	Novel agents for primary central nervous system lymphoma: evidence and perspectives. <i>Blood</i> , 2018, 132, 681-688.	1.4	23
39	Premature Discontinuation of Prospective Clinical Studies Approved by a Research Ethics Committee – A Comparison of Randomised and Non-Randomised Studies. <i>PLoS ONE</i> , 2016, 11, e0165605.	2.5	22
40	Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. <i>BMC Cancer</i> , 2019, 19, 287.	2.6	22
41	Management of Multiple Myeloma in Pregnancy: Strategies for a Rare Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 190-197.	0.4	21
42	Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated meta-research analysis. <i>PLoS Medicine</i> , 2022, 19, e1003980.	8.4	21
43	Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 999-1000.	2.4	20
44	Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. <i>PLoS Medicine</i> , 2016, 13, e1002046.	8.4	20
45	Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. <i>Journal of Clinical Epidemiology</i> , 2019, 114, 49-59.	5.0	20
46	An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. <i>Journal of Clinical Epidemiology</i> , 2016, 69, 152-160.	5.0	19
47	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. <i>Trials</i> , 2018, 19, 505.	1.6	17
48	How to use FDA drug approval documents for evidence syntheses. <i>BMJ: British Medical Journal</i> , 2018, 362, k2815.	2.3	17
49	Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. <i>Blood</i> , 2012, 120, 302-302.	1.4	17
50	Primary CNS Lymphoma – Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 281-283.	2.0	16
51	Para-aortic lymph node metastasis in malignant dysgerminoma of the ovary. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2009, 88, 1288-1290.	2.8	15
52	Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 73-83.	5.0	15
53	The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1257-1264.	1.8	13
54	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. <i>BMJ Open</i> , 2016, 6, e011148.	1.9	13

#	ARTICLE	IF	CITATIONS
55	The role of additional radiotherapy for primary central nervous system lymphoma. The Cochrane Library, 2014, , CD009211.	2.8	12
56	Immunotherapies in Early and Advanced Renal Cell Cancer. Progress in Tumor Research, 2015, 42, 1-10.	0.1	12
57	Reliability of Trial Information Across Registries for Trials With Multiple Registrations. JAMA Network Open, 2021, 4, e2128898.	5.9	12
58	The stromal cell-derived factor-1 α dependent migration of human cord blood CD34 ⁺ haematopoietic stem and progenitor cells switches from protein kinase C (PKC) α dependence to PKC α independence upon prolonged culture in the presence of Flt3 ligand and interleukin-6. British Journal of Haematology, 2008, 142, 831-835.	2.5	11
59	Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation. PLoS ONE, 2019, 14, e0210669.	2.5	10
60	Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT) rationale and design for an international collaborative study. Trials, 2020, 21, 731.	1.6	10
61	ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceded by clonally related lymphomatoid papulosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 763-767.	2.8	9
62	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Journal of Molecular Diagnostics, 2020, 22, 1300-1307.	2.8	9
63	Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects. Trials, 2020, 21, 896.	1.6	9
64	Fibrates for primary prevention of cardiovascular disease events. , 2012, , .		8
65	Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit. Journal of Clinical Epidemiology, 2017, 82, 12-19.	5.0	8
66	Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Network Open, 2021, 4, e210380.	5.9	8
67	Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study. Journal of Clinical Epidemiology, 2021, 139, 340-349.	5.0	7
68	Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation - protocol of the ICEM study. Systematic Reviews, 2014, 3, 46.	5.3	5
69	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ, The, 2014, 349, g4921-g4921.	6.0	5
70	Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study design. Trials, 2013, 14, 335.	1.6	4
71	Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open, 2019, 4, e000596.	4.5	4
72	Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIrit Recommendations in Switzerland, CANada and GERMany (ASPIRE-SCAGE). BMJ Open, 2022, 12, e053417.	1.9	3

#	ARTICLE	IF	CITATIONS
73	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. Expert Review of Hematology, 2016, 9, 123-135.	2.2	2
74	CNS border posts against rituximab?. Lancet Oncology, The, 2019, 20, 169-170.	10.7	2
75	Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials. JAMA Network Open, 2021, 4, e2131503.	5.9	2
76	Characteristics and survival of patients with cancer with intended off-label use—a cohort study. BMJ Open, 2022, 12, e060453.	1.9	2
77	Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition. Annals of Oncology, 2016, 27, vi24.	1.2	1
78	Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation - a Multicenter Retrospective Analysis. Blood, 2011, 118, 3089-3089.	1.4	1
79	First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis. Blood, 2012, 120, 3655-3655.	1.4	1
80	Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials. Blood, 2016, 128, 5385-5385.	1.4	1
81	Stem Cell Migration in Health and Disease. Translational Research in Biomedicine, 2009, , 7-27.	0.4	0
82	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis. Annals of Oncology, 2017, 28, v382.	1.2	0
83	Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey. BMJ Open, 2020, 10, e034565.	1.9	0
84	Modulation of Hematopoietic Stem/Progenitor Cell Migration. , 2009, , 57-77.		0
85	FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma. Blood, 2011, 118, 2687-2687.	1.4	0
86	High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma –Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group. Blood, 2014, 124, 2527-2527.	1.4	0
87	Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors.. Journal of Clinical Oncology, 2016, 34, e14513-e14513.	1.6	0
88	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group. Blood, 2016, 128, 781-781.	1.4	0
89	Ifosfamide and Carboplatin Based (R-DeVIC) Salvage Therapy in Patients with Relapsed/Refractory PCNSL - a Multicentre Retrospective Analysis. Blood, 2018, 132, 1705-1705.	1.4	0